IPSEN has announced that its acromegaly and carcinoid syndrome treatment Somatuline (lanreotide) has been given an extended PBS listing to include community access under the Section 100 Highly Specialised Drugs Program (HSDP).
This means that once therapy has been initiated and the patient is stabilised on Somatuline Autogel, they can access treatment at a pharmacy within their local community, rather than having to travel to a major hospital.
Patient eligibility criteria for Somatuline Autogel are unchanged.
The above article was sent to subscribers in Pharmacy Daily's issue from 13 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Apr 18
